<DOC>
	<DOCNO>NCT01433627</DOCNO>
	<brief_summary>This protocol describe study compare intend trans-radial versus trans-femoral intervention bivalirudin monotherapy versus current European standard care consist unfractionated heparin ( UFH ) plus provisional use glycoprotein IIb/IIIa inhibition via use one three available agent market ( e.g . abciximab , tirofiban eptifibatide ) patient ( ≥18 year ) ACS , intend invasive management strategy . This study conduct compliance Good Clinical Practices ( GCP ) include Declaration Helsinki applicable regulatory requirement .</brief_summary>
	<brief_title>Minimizing Adverse Haemorrhagic Events TRansradial Access Site Systemic Implementation angioX</brief_title>
	<detailed_description>The use combine antithrombotic therapy last two decade decrease risk heart attack percutaneous coronary intervention substantially also associate significant increase bleeding risk . Therapies strategies maintain benefit see currently available antithrombotic therapy lower bleed risk therefore great clinical importance . Indeed , major bleed currently common non-cardiac complication therapy patient coronary artery disease undergone percutaneous coronary intervention ( PCI ) . Bleeding patient acute coronary syndrome ( ACS ) associate increase risk long term mortality morbidity , relationship currently think causal . Therefore ' reducing frequency bleed event maintain efficacy important goal management patient ACS . The common site bleed invasively manage patient ACS femoral artery puncture site use heart catheterization The MATRIX study multi-centre , prospective , randomised , open-label , 2 2 factorial comparison trans-radial vs. trans-femoral intervention bivalirudin vs. unfractionated heparin provisional use glycoprotein IIb/IIIa inhibitor . Objectives : 1 . To demonstrate trans-radial intervention compare femoral access site associate low rate composite endpoint death , MI stroke within first 30 day randomization acute coronary syndrome patient undergo early invasive management . 2 . To demonstrate bivalirudin infusion compare standard care therapy consist unfractionated heparin provisional use glycoprotein IIb/IIIa inhibitor associate low rate composite endpoint death , MI stroke within first 30 day randomization acute coronary syndrome patient undergo early invasive management . Patients randomly assign receive bivalirudin randomize stop bivalirudin infusion end PCI prolong bivalirudin infusion rate 0.25 mg/kg/hour least 6 hour completion PCI . The primary hypothesis sub-randomization prolong post-intervention bivalirudin infusion superior bivalirudin post-PCI infusion respect net composite outcome consist death , MI , stroke , urgent TVR , stent thrombosis BARC-defined type 3 5 bleeding event within 30 day . Secondary objective sub-randomization prolong bivalirudin versus post-PCI infusion bivalirudin group consist component primary composite endpoint entire follow-up duration</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Bivalirudin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Hirudins</mesh_term>
	<mesh_term>Tirofiban</mesh_term>
	<mesh_term>Eptifibatide</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<criteria>NSTEACS definition : Patients follow criterion eligible : 1. history consistent new , worsen ischemia , occur rest minimal activity ; 2. enrollment within 7 day recent symptom ; 3. plan coronary angiography possible indication PCI ; 4. least 2 follow criterion : 1 . Aged 60 year old , 2 . Troponin T I creatine kinase MB upper limit normal ; 3 . Electrocardiograph change compatible ischemia , ie , ST depression 1 mm great 2 contiguous lead , Twave inversion 3 mm , dynamic ST shift ; STEMI definition : ) chest pain &gt; 20 min electrocardiographic STsegment elevation ≥1 mm two contiguous electrocardiogram ( ECG ) lead , new leave bundlebranch block , inferolateral myocardial infarction ( MI ) ST segment depression ≥1 mm ≥2 lead V13 positive terminal T wave ii ) admission either within 12 h symptom onset 12 24 h onset evidence continue ischemia previous lytic treatment . 1 . Patients give inform consent life expectancy &lt; 30 day 2 . Allergy/intolerance Bivalirudin unfractionated heparin . 3 . Stable silent CAD indication coronary angiography 4 . Treatment LWMH within past 6 hour 5 . Treatment GPI previous 3 day 6 . Absolute contraindication allergy premedicated iodinated contrast study medication include aspirin clopidogrel . 7 . Contraindications angiography , include limit severe peripheral vascular disease . 8 . If know pregnant nursing mother . Women childbearing age ask pregnant think may pregnant . 9 . If know creatinine clearance &lt; 30 mL/min dialysis dependent . 10 . Previous enrollment study . 11 . Treatment investigational drug device within 30 day precede 12 . Randomisation plan use investigational drug device trial . 13 . Severe uncontrolled hypertension ( defined persistent systolic blood pressure high 220 mmHg despite medical treatment ) . 14 . Subacute bacterial endocarditis 15 . PCI previous 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>acute coronary syndrome</keyword>
	<keyword>myocardial infarction</keyword>
	<keyword>access site</keyword>
	<keyword>bivalirudin</keyword>
	<keyword>bleeding</keyword>
</DOC>